OasisLMS

Eric Dodgson PharmD

Join Eric Dodgson for an overview of the latest developments in gene and cellular therapies. This webinar will compare CAR-T therapy with other gene therapy approaches, review updates in CAR-T-associated adverse event management, and examine the role of busulfan monitoring during gene therapy conditioning, including considerations for patients with sickle cell disease.


Learning Highlights:

• Compare CAR-T therapy with other gene therapy approaches.
• Review updates in CAR-T-associated hyperinflammatory adverse events, including CRS, ICANS, and IEC-HS.
• Understand the role of busulfan therapeutic drug monitoring during gene therapy conditioning.
• Identify risks associated with busulfan overexposure and underexposure.
• Explore the impact of busulfan exposure in patients with sickle cell disease.

The Webinar and post-webinar evaluation is available for 30 days.

Target Audience
This session is open to all registered nurses and allied health care providers.

• Compare and contrast CAR-T therapy to other forms of gene therapy
• Describe the updates in CAR-T associated hyperinflammatory adverse events, including Cytokine Release Syndrome (CRS), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), and Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)
• Explain the utility of busulfan targeting for gene therapy conditioning, and the risks associated with over and under exposure to busulfan
• Apply the risks associated with busulfan exposure to the Sickle Cell Patient Population

APHON will provide 1 nursing continuing professional development contact hour for successful completion of the webinar. Association for Pediatric Hematology Oncology Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. Provider approved by the California Board of Registered Nursing, Provider Number 14513. None of the planners for this activity have relevant financials relationship(s) to disclose with ineligible companies.

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. You may claim 1 NCPD in one of the following ILNA categories:

Please reach out to the Education Team at education@aphon.org with your name, the email associated with your APHON account, and the above ILNA category you would like to have reflected on your certificate and APHON can update your completion certificate to reflect your choice.

Questions or concerns? Contact education@aphon.org.